

REMARKS

The original Sequence Listing has been replaced with a Substitute Sequence Listing, which corrects minor typographical errors in the original Sequence Listing.

Specifically, in the first line <150>, application number "09/066,352" has been changed to "09/006,352" in order to correctly identify the application of which we claim priority. This application number is correctly identified on page 1 line 2 of the specification.

SEQ ID NO:17, which corresponds to the HELDI06R sequence shown in Figure 6, contained three errors. The following corrections have been made to SEQ ID NO:17 of the sequence listing: a "g" was inserted between nucleotides 96 and 97; a "c" was inserted between nucleotides 218 and 219; and the "c" at nucleotide 322 was changed to a "g". Each of these changes is supported by Figure 6 of the specification. The insertion of the "g" nucleotide between nucleotides 96 and 97 and the insertion of the "c" between nucleotides 218 and 219, changed the locations of the "n" nucleotides. Accordingly, feature location positions (159)..(160), (163), (180), (204), (206), (211), (229), (246), (275), (320), (328), (351), (370), (376), (389), (392), (400), (405), (419), (435)..(436), (444), (458), (464), (472), (480)..(482), (484), and (494), have been changed to (160)..(161), (164), (181), (205), (207), (212), (231), (248), (277), (322), (330), (353), (372), (378), (391), (394), (402), (407), (421), (437)..(438), (446), (460), (466), (474), (482)..(484), (486), and (496).

Statements Under 37 C.F.R. § 1.825(a) and § 1.825(b)

In accordance with 37 C.F.R. § 1.825(a), the undersigned attorney for Applicants hereby states that the amendments contained in the Substitute Sequence Listing submitted herewith are supported in the application as filed, particularly in Figure 6, as indicated above, and that these amendments introduce no new matter.

In accordance with 37 C.F.R. § 1.825(b), the undersigned attorney for Applicants hereby states that the information contained in the computer readable form of the Substitute Sequence Listing submitted herewith is identical to the information contained in the paper copy of the Substitute Sequence Listing submitted herewith.


Applicants believe that the paper and computer readable copies of the Substitute Sequence Listing, submitted herewith, bring the application into compliance with 37 C.F.R. §§ 1.821-1.825.

CONCLUSION

The required surcharge fee of \$130.00 for late filing of the declaration under 37 C.F.R. § 1.16(e) may be charged to Deposit Account No. 08-3425. Should any additional fees be deemed necessary, please charge such fees to Deposit Account No. 08-3425. A duplicate copy of this paper is submitted herewith.

Respectfully submitted,

Date: July 31, 2000


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (phone)

JK/MS/rc